Besterman Aaron D, Adams David J, Wong Nicole R, Schneider Benjamin N, Mehta Sunil, DiStefano Charlotte, Wilson Rujuta B, Martinez-Agosto Julian A, Jeste Shafali S
Division of Child and Adolescent Psychiatry, University of California San Diego Department of Psychiatry, San Diego, CA; Rady Children's Hospital of San Diego, San Diego, CA; Rady Children's Institute for Genomic Medicine, San Diego, CA.
David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA; Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, CA.
Genet Med. 2025 Feb;27(2):101333. doi: 10.1016/j.gim.2024.101333. Epub 2024 Dec 18.
Patients with neurodevelopmental disorders (NDDs) have high rates of neuropsychiatric comorbidities. Genomic medicine may help guide care because pathogenic variants are identified in up to 50% of patients with NDDs. We evaluate the impact of a genomics-informed, multidisciplinary, neuropsychiatric specialty clinic on the diagnosis and management of patients with NDDs.
We performed a retrospective study of 316 patients from the University of California, Los Angeles Care and Research in Neurogenetics Clinic, a genomics-informed multidisciplinary clinic.
Among the 246 patients who underwent genetic testing, 41.8% had a pathogenic or likely pathogenic variant. Patients had 62 different genetic diagnoses, with 12 diagnoses shared by 2 or more patients, whereas 50 diagnoses were found in only single patients. Genetic diagnosis resulted in direct changes to clinical management in all patients with a pathogenic or likely pathogenic variant, including cascade testing (30.6%), family counseling (22.2%), medication changes (13.9%), clinical trial referral (2.8%), medical surveillance (30.6%), and specialty referrals (69.4%).
A genomics-informed model can provide significant clinical benefits to patients with NDDs, directly affecting management across multiple domains for most diagnosed patients. As precision treatments advance, establishing a genetic diagnosis will be critical for proper management. With the growing number of rare neurogenetic disorders, clinician training should emphasize core principles of genomic medicine over individual syndromes.
神经发育障碍(NDDs)患者神经精神共病发生率很高。基因组医学可能有助于指导治疗,因为在高达50%的NDDs患者中可鉴定出致病变异。我们评估了一个基于基因组学信息的多学科神经精神专科诊所对NDDs患者诊断和管理的影响。
我们对来自加利福尼亚大学洛杉矶分校神经遗传学诊所(一个基于基因组学信息的多学科诊所)的316例患者进行了回顾性研究。
在246例接受基因检测的患者中,41.8%有致病或可能致病的变异。患者有62种不同的基因诊断,其中12种诊断由2例或更多患者共有,而50种诊断仅在单例患者中发现。基因诊断导致所有有致病或可能致病变异的患者的临床管理发生直接变化,包括级联检测(30.6%)、家庭咨询(22.2%)、药物调整(13.9%)、临床试验转诊(2.8%)、医学监测(30.6%)和专科转诊(69.4%)。
基于基因组学信息的模式可为NDDs患者提供显著的临床益处,直接影响大多数已确诊患者多个领域的管理。随着精准治疗的发展,建立基因诊断对正确管理至关重要。随着罕见神经遗传疾病数量的增加,临床医生培训应强调基因组医学的核心原则而非个别综合征。